There is a need for unbiased estimates of cause-specifi c mortality by etiology in patients with liver cirrhosis. The aim of this study is to use nationwide linked electronic routine healthcare data from primary and secondary care alongside the national death registry data to report such estimates.
INTRODUCTION
Cirrhosis of the liver is increasing worldwide at an alarming rate ( 1 ) . In the United Kingdom, the increase is faster than the four most common diagnosed cancers (breast, bowel, lung, and prostate) ( 2 ) . Mortality in people with cirrhosis is high, with 5-year survival rates reported to be similar to that of bowel cancer ( 3 ) . However, contemporary knowledge of what people with cirrhosis die from and how this varies by etiology of their cirrhosis is lacking. Such information can be important to demonstrate areas where premature mortality could be reduced and guide evidence-based practice in patient follow-up. For example, a recent matched cohort study of patients experiencing a gastrointestinal bleed showed that over half the excess risk of death (i.e., the risk of death in cases compared with that of controls) was due to nongastrointestinal comorbidity, warranting non-gastrointestinal assessment aft er a bleeding episode ( 4 ) . To date, the excess cause of death of patients with liver cirrhosis of all etiologies estimated from a population-based study has not been determined. Studies
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Primary-care data
Th e Clinical Practice Research Datalink (CPRD) is a longitudinal electronic database consisting of anonymized primary-care records for over 10 million patients in the United Kingdom, collected since 1987. Data are coded using the Read code system ( 11 ) . Participating practices are assigned an up-to-standard date on completion of regular audits confi rming data quality and completeness; patient-level data are also assessed ( 12 ) . Th e CPRD has previously been shown to be a representative of the population of the United Kingdom ( 13 ) .
Secondary-care data
Th e Hospital Episodes Statistics database comprises statutory records of all admissions (excluding outpatients) conducted in National Health Service hospitals and independent treatment centers in England, since 1989. For each period of time under the care of a consultant, a patient is assigned a primary diagnosis and up to 19 secondary diagnoses, coded using the ICD-10 (International Classifi cation of Diseases, tenth revision), and/or up to 24 recorded procedures coded using the OPCS4 (Offi ce of Population, Censuses and Surveys' classifi cation of surgical operations and procedures, fourth revision). Linked Hospital Episodes Statistics data are available for patients registered at consenting CPRD practices in England. Characteristics of patients in linked practices do not differ from those in non-linked practices ( 14 ) .
Death registry data
Th e Offi ce for National Statistics provides death registry data for CPRD practices that are linked to the Hospital Episodes Statistics. Th e data consist of date of death and the underlying cause of death obtained from death certifi cation and completed according to World Health Organization guidelines ( 15 ) , coded using International Classifi cation of Diseases versions 9 (ICD-9) and 10 (ICD-10).
Study population
We have described the study population in detail previously ( 2 ) . In brief, we defi ned cirrhosis in primary care if a person had a record containing a Read code for cirrhosis, esophageal varices and/or portal hypertension in the CPRD. Th is code list has been previously validated using medical notes ( 16 ) . We developed code lists for cirrhosis diagnosis in secondary care from ICD-10 and OPCS4 codes. More than 90% of patients with a diagnosis in secon dary care were reported to have supportive evidence of liver cirrhosis, either on their death certifi cate, in their primary-care records, or in the free text section of their primary-care records ( 2 ) . For each patient we assigned the date of diagnosis as the fi rst date associated with a Read or ICD-10/OPCS4 code for cirrhosis. Incident diagnoses in either CPRD or Hospital Episodes Statistics for patients (≥18 years) were identifi ed between January 1998 and December 2009.
Etiology
For each patient we searched all medical records for evidence of viral hepatitis and autoimmune (AI) and metabolic diseases. We have described the diagnostic codes used for each etiology in detail previously ( 2 ) . Etiology was ascribed in a hierarchical manner of viral hepatitis, AI or metabolic disease, and alcoholic cirrhosis. All remaining patients with no recorded etiology were defi ned as having unspecifi ed etiology. Although patients may have a record of more than one type of underlying disease, using four mutually exclusive groups minimizes the loss of power in the analysis of these subgroups.
Stage of disease
We defi ned stages of disease, within 1 year from diagnosis, as agreed at the Baveno IV consensus conference ( 17 ) . For the analyses in this study, we grouped stages 1 and 2 (cirrhosis with or without non-bleeding esophageal varices, with no ascites) as compensated cirrhosis and stages 3 and 4 (cirrhosis with ascites and/or bleeding esophageal varices) as decompensated cirrhosis.
Causes of death
We used the underlying cause of death code provided by the Offi ce for National Statistics, derived using standardized guidelines from the information available on death certifi cates ( 18 ) . Where necessary, we mapped ICD-9 codes to ICD-10 codes; if mapping was LIVER A Competing Risks Analysis not possible, the cause of death was considered missing. Causes of death were categorized using the main ICD-10 chapter headings as follows: the liver (K70-K77), which include alcoholic liver disease, toxic liver disease, hepatic failure, chronic hepatitis, fi brosis and cirrhosis of the liver, other infl ammatory liver diseases, other diseases of the liver, and liver disorders in diseases classifi ed elsewhere; in addition, malignant neoplasm of the liver and intrahepatic bile ducts C22, which includes hepatocellular carcinoma (C22.0), esophageal and gastric varices (I85, I864, and I982); nonliver neoplasm (C00-D48 excluding C22); circulatory (I00-I99, excluding I85, I864, and I982) and respiratory (J00-J99). All other causes of deaths or missing ICD codes were categorized as 'Other. '
Comparison group
Controls were selected from the general population (patients from CPRD practices, who did not have a liver cirrhosis diagnosis). We calculated a random pseudo-diagnosis date during the incident study period by selecting a random date between the registration start and end dates. Age was then calculated at this date and controls aged 18 years and onwards at the time of pseudo-diagnosis were included. Th irty controls were frequency matched to each case by age at diagnosis within 5-year age bands.
Statistical analysis
We excluded patients whose diagnosis of cirrhosis occurred on the same day as death. We described patient characteristics by etiology (exposure) and used χ 2 -tests for signifi cance testing. Th e fi ve grouped causes of death were the principal outcomes.
Crude mortality rates . Person-time at risk commenced at diagnosis of cirrhosis or pseudo-diagnosis date and ended at the date of death or censoring of the patient record (earliest of date the patient left the practice or the last data collection date: 30 December 2010 or liver transplant date). Cause-specifi c mortality rates were calculated by dividing the number of deaths due to each cause by the total person-years of follow-up. Rates were calculated for each major subgroup, and hepatocellular carcinoma specifi cally, for both cases and those without liver cirrhosis.
Adjusted analysis . As stated previously, conventional survival analysis provides probabilities of surviving a particular cause of death, e.g., cancer, in the hypothetical world where it is not possible to die from anything else, say myocardial infarction ( 19, 20 ) . In contrast, competing risks theory allows us to calculate real-world probabilities where a patient is not only at risk of dying from a specifi c cause but also from any other cause of death. To adjust for this bias, we determined the cumulative incidence function (i.e., the predicted cumulative risk of death) by 5 years from diagnosis for each specifi c cause of death. Th e 5-year cutoff point was used, as the majority of deaths had occurred by then. Th e cumulative incidence function adjusts for competing risks by calculating the cumulative probability of dying from a specifi c cause at each time point having survived to that time without a death from any other cause. We derived the cumulative incidence from baseline survival functions and estimates of instantaneous hazards from causespecifi c Cox proportional regression models, a well-established approach ( 10, 21, 22 ) . Th e models were adjusted for age and sex, as we considered these to be a priori confounders. We stratifi ed the cumulative incidence of death by etiology and whether patients were compensated or decompensated at diagnosis.
We calculated the excess risk of death for each specifi c cause as the diff erence between the cumulative incidence of death for cases and the cumulative incidence of death for those without liver cirrhosis; 95% confi dence intervals (CIs) were calculated by bootstrapping (50 iterations). Th e cumulative incidence of death and excess risk for each cause of death was plotted using stacked graphs by etiology subgroup. Stata version 12/MP4 (StataCorp LP, College Station, TX) was used for all statistical analyses.
Subgroup analysis
We identifi ed patients' last smoking record as the latest but not closer than 6 months before diagnosis (pseudo-diagnosis date for those without liver cirrhosis). Smoking status was classifi ed as 'ever-smoker' (current/ex-smoker), 'non-smoker, ' or 'missing' . We then determined whether the excess risk of death diff ered between ever-smokers and non-smokers.
RESULTS
Study population
Our cohort consists of 5,118 patients with an incident diagnosis of liver cirrhosis frequency matched on age to 152,903 people without liver cirrhosis. Th e median follow-up was 1.88 (interquartile range: 0.40, 4.27) and 3.13 (interquartile range: 1.38, 6.14) years for those with and without liver cirrhosis, respectively. Age, sex, and stage of disease varied signifi cantly by etiology subgroup, P <0.001 ( Table 1 ). In particular, decompensation around diagnosis was more prevalent among patients of alcohol and unspecifi ed etiology (48.2% and 45.4% respectively) than among the other etiology subgroups (AI/metabolic 27.1%; viral hepatitis 32.6%).
Th e comparison group had a smaller proportion of men and a smaller proportion of ever-smokers than the study cohort. Th e proportion of ever-smokers among those without liver cirrhosis was similar to that of the unspecifi ed etiology subgroup ( Table 1 ). Table 2 shows the crude mortality rates for those with and without liver cirrhosis. Overall, for people with cirrhosis there were 2,546 (49.7%) deaths during 13,938 person-years of follow-up and the overall mortality rate was 18.3 (17.6, 19) per 100 person-years. Of all deaths, approximately half were liver-related ( n =1,293, 50.8%). Just under two-thirds of all deaths occurred within 1 year of diagnosis ( n =1,513, 59.4%) and again around half were liverrelated ( n =819, 54.1%). Overall, liver-related deaths were greater at all time points than any other single cause of death. Mortality in the comparison group was a fi ft h of that in people with cirrhosis, 2.98 (95% CI: 2.94, 3.03) per 100 person-years with the most common cause of death being circulatory (32.7%) followed by nonliver neoplasm (29.4%), other (24.8%), respiratory (12.5%) and the liver (0.7%), the latter being 50 times less than that of people with cirrhosis. Table 3 shows crude mortality rates stratifi ed by etiology. For all specifi ed etiologies, liver-related death was the most common cause of death. Non-liver neoplastic death was the main cause of death among patients of unspecifi ed etiology and the rate was higher than that seen in the other etiology subgroups.
Crude mortality rates
We have looked at the specifi c type of liver-related deaths by etiology. Th e main diff erence was a signifi cantly higher proportion of people dying due to alcoholic liver disease (ICD-10 code K709) in the alcohol subgroup compared with the other subgroups. Th e proportion of liver-related deaths due to alcoholic liver disease were 20.2% ( n =24), 9.6% ( n =10), 42.1% ( n =384), and 2.5% ( n =4) in viral hepatitis, AI/metabolic, alcohol, and unspecifi ed etiology groups, respectively ( P <0.01).
Hepatocellular carcinoma as the cause of death
Of all cases who died, 96 (3.8%) deaths were due to hepatocellular carcinoma (mortality rate=0.68 (95% CI: 0.56, 0.84) per 100 person-years); this varied by etiology ranging from 0.5 to 1.5 per 100 person-years for patients of alcohol and viral hepatitis etiology, respectively (see Table 3 ). Th e equivalent hepatocellular carcinoma rate among controls was 0.003 (95% CI: 0.002, 0.004).
Among those who died due to a liver-related cause, hepatocellular carcinoma was the underlying cause of death for 7.4% (96 out of 1,302) and 13.5% (17 out of 126) in those with and without liver cirrhosis, respectively. In compensated and decompensated patients, the proportion of liver-related deaths attributed to hepatocellular carcinoma was 13.3% and 3.2%, respectively. Table 4 shows the cumulative incidence and excess risk of death by 5 years aft er diagnosis, aft er adjusting for competing risks, age and sex, and stratifi ed by stage of disease. As the pattern for cumulative incidence and excess risk are similar, we have focused on the latter. In compensated patients, the excess risk of death due to liver-related death was higher than non-liver causes of death combined for all etiologies (apart from unspecifi ed), with those of alcoholic etiology representing the highest excess risk of 30.8% (95% CI: 27.9, 33.1). Th is compares with an excess risk of all non-liver-related deaths combined of only 9.9% in patients with alcoholic cirrhosis. In people with cirrhosis of unspecifi ed etiology, the excess risk of non-liver-related death was 10.7% (of which 7.7% was attributed to non-liver neoplasm death) and that of liver-related mortality was 6.7%. For patients of unspecifi ed etiology, the three most common types of the 181 non-liver-related neoplastic deaths were pancreatic ( n =32, 17.7%), primary site unspecifi ed ( n =25, 13.8%), and the lung ( n =17, 9.4%). Figure 1 displays the excess risk of death compared with those without liver cirrhosis, in compensated patients, at every time 
Risk of mortality adjusted for competing events
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In decompensated patients, the excess risk of death due to liverrelated reasons was higher than any other cause of death for all etiologies and all 95% CIs for liver-related excess mortality excluded zero ( Table 4 ).
Subgroup analysis: smoking status
Supplementary Tables 1 and 2 show the cumulative incidence and excess mortality by etiology for ever-smokers and non-smokers, respectively. Th ere was a similar pattern to that without stratifi cation by smoking status. For example, in compensated patients the highest excess of non-liver neoplasm death was seen in patients of unspecifi ed etiology, in both eversmokers (9.24%, 95% CI: 7.67, 10.81) and non-smokers (5.87%, 95% CI: 4.68, 7.05).
DISCUSSION
Main fi ndings
We have demonstrated how the cause of death in people with cirrhosis varies by the underlying etiology of liver disease and stage of disease. Aft er adjusting for competing risks, people with compensated and decompensated cirrhosis of alcohol, viral hepatitis, and AI/metabolic etiology were more likely to die from liver-related causes than any other cause of death, when compared with the general population. In particular, people of alcohol etiology had the highest 5-year excess risk of liver-related death compared with any other compensated etiology subgroup. Importantly, however, people with unspecifi ed cirrhosis, who were compensated at diagnosis, had a higher excess risk of non-liver-related death than liver-related death.
Most of the non-liver-related deaths in compensated unspecifi ed cirrhosis patients were due to non-liver neoplastic deaths that occurred independently of smoking status. Knowledge of the risk of non-liver neoplasm (in particular, pancreatic) during an early point up to 5 years, for each etiology subgroup. Th e fi gure highlights clearly that at every time point, liver-related death is associated with the highest excess risk in those with viral hepatitis, AI/metabolic, and alcohol etiology, whereas those of unspecifi ed etiology have a higher excess risk of non-liver-related causes of death combined throughout the 5 years post diagnosis than that of liver-related cause of death. Excludes hepatocellular carcinoma. c Other includes 1,470 deaths (8% of total) with missing ICD-10 codes for those without liver cirrhosis and 81 deaths (3.2% of total) with missing ICD-10 codes for cases. stage of disease should provide an opportunity for clinicians to be vigilant when reviewing these patients.
Strengths/limitations
Our study has the advantages of its large size, general population setting, adjustment for competing risks, and a design that minimizes selection bias. An important limitation to consider is the potential of misclassifi cation with respect to identifying patients' etiology, which is crucial to discuss given that it is our primary exposure variable. It is possible, for example, that we have underreported, to some degree, the number of people with alcohol etiology, both owing to our imposed hierarchy of etiologies and as reporting of alcohol consumption in medical notes is known not to refl ect true alcohol consumption ( 23 ) . However, we are confi dent that using a combination of both primary-and secondary-care healthcare records has provided us with as much information as would be obtained if we were to conduct a casenote review. For the etiologies that are diseases, we expect these to have a high specifi city as a recent study has reported high validation for the diagnosis of AI hepatitis in the CPRD ( 24 ) and, in addition, a systematic review showed that the validation of many other diagnoses recorded in the CPRD was high ( 25 ) . Compared with other published studies in the United Kingdom ( 6, 8, 16 ) , it would appear that our coverage of etiology (that is, the proportion of each type of subgroup) is as good, if not better, probably because we are the fi rst study to use linked databases and hence Excludes hepatocellular carcinoma. Cumulative incidence is the adjusted predicted risk of death, adjusted for age, sex, and other causes of death. The absolute excess is the cumulative incidence in cases minus the cumulative incidence in those without liver cirrhosis. c Includes missing cause of death. CIs calculated using Bootstrapping with 50 iterations.
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fore, assigning the stage of disease around diagnosis is imprecise. It is possible that we have underestimated the number of people diagnosed with decompensated cirrhosis; however, we have minimized this as best as we can by identifying the fi rst clinical symptom up to 1 year before the diagnosis date, thus taking into account that the diagnosis date may not be when the person fi rst became symptomatic. Finally, by calculating cumulative incidence and adjusting for competing events we have minimized the likelihood of overestimating the risk of death for each specifi c cause.
Comparison with other studies
Our study is probably best compared with a large Danish nationwide cohort study, which identifi ed 10,154 patients with liver cirrhosis admitted to the hospital during the period 1982-1989 ( 9 ). Of the 69% of patients who died by 1993, 51% deaths were attributed to causes related to cirrhosis (similar to this current study). In addition, similarly, the nonspecifi ed cirrhosis group had a greater excess risk of cancer-related death (Standardized Mortality Ratio (SMR) of 8.8) than the alcoholic cirrhosis group (SMR of only 4.9). When comparing the cause-specifi c risks of death with the general population the authors have not reported absolute risk of death, which limits the practical translation of their fi gures into the clinical arena. One further limitation, as mentioned by the authors, is lack of lifestyle data such as smoking status, which they have not been able to adjust for.
A commonly referenced study describing the cause-specifi c mortality in patients with cirrhosis in the United Kingdom is the aforementioned paper by Roberts et al. ( 8 ) , which used data from hospital discharge statistics in Oxford region during 1968-1999. Th e authors included patients admitted for any chronic liver disease (ICD-10 K70, K73, K74, and K76.0), a much broader case defi nition than our specifi c measure of cirrhosis diagnosis including patients who do not necessarily have cirrhosis, e.g., people with multiple healthcare records. Despite the large size of our cohort, we were unable to carry out subgroup analyses among those with multiple etiologies, e.g., viral hepatitis and alcohol. Had we used more than four subgroups, this would have resulted in a lack of power and imprecision due to small numbers of events (deaths). In addition, it is likely to be that there would be some misclassification of the joint etiologies and that coupled with the small numbers of events would mean that we would be unable to accurately assess the relationships with cause-specifi c deaths. Th e main limitation of having four mutually exclusive categories is that the liver-related mortality rates we have provided in our viral hepatitis and AI/metabolic etiology subgroups may be overestimates of the true risk in those with a single etiology.
Another limitation is potential ascertainment bias. It is possible that there is a recording bias with doctors fi lling in death certifi cates more likely to record liver disease as the cause of death in patients known to have liver cirrhosis compared with those without cirrhosis. Furthermore, it is well documented that the cause of death information taken from death certifi cates is oft en lacking in accuracy and completeness. Diagnostic and coding errors oft en occur and multiple disease processes can mask the true underlying causes of death ( 26 ) . However, the Offi ce for National Statistics data based on World Health Organization guidelines is the most pragmatic and only feasible method to ascertain the cause of death in a standardized way for such a large study population. In addition, a recent study has shown that misclassifi cation of the cause of death may only bias estimates in patients older than 85 years, a small proportion of our study cohort ( n =183, 3.6%) ( 21 ) . Finally, the underlying cause of death was used to avoid the possible eff ect of changes in coding requirements over time ( 27 ) .
Th ere may be some misclassifi cation with respect to stage of disease. In the United Kingdom, once a patient is diagnosed with cirrhosis they do not necessarily always receive surveillance; there- alcoholic liver disease (K70.9). Aft er following patients up to 1 year, they found that liver disease was the certifi ed underlying cause of death for 51% of patients who died, similar to our study (53.8%). Cause-specifi c SMRs by etiology were determined and, also similar to our fi ndings, the unspecifi ed cirrhosis subgroup had a higher relative risk of death from neoplastic causes (SMR 9.6) than the alcoholic subgroup (3.2) and all other etiology subgroups. Th ose people with cirrhosis of alcoholic etiology had a higher SMR for liver-related mortality compared with all other etiology subgroups. However, unlike our fi ndings, the SMR for liver-related death was higher than non-liver-related deaths combined for the unspecifi ed group. Th e authors did not have access to clinical or demographic data; therefore, they were unable to categorize patients by severity of cirrhosis or smoking status, as has been done in the present study, and therefore we cannot make a direct comparison with some of the fi gures we have displayed. We found that 3.8% of all deaths were due to hepatocellular carcinoma and rates varied from 0.5 to 1. Th eir rates of hepatocellular carcinoma were slightly lower than ours (0.34 and 0.25 per 100 person-years for alcohol and unspecifi ed cirrhosis, respectively). Other studies from Europe, Japan, and America reported substantially higher rates of hepatocellular carcinoma (30) (31) (32) (33) (34) . Our rates therefore are not that dissimilar from equivalent database epidemiological studies from Denmark with which our work is probably best compared.
Clinical implications
Predicting future mortality rates is important, as such knowledge may enable improved planning of health services and prioritization of limited public health resources. For example, the fi nding that the alcohol etiology group had the highest excess risk of liver-related death compared with the other subgroups, when diagnosed at an early stage of disease and given the rise in the occurrence of alcohol-related cirrhosis previously reported ( 1, 2 ) , implies that the planning of future services should allow for the number of people requiring liver services in England and other countries. Given that the most common liver-related death among those with alcohol cirrhosis is alcoholic liver disease, this highlights the importance of attempting to reduce alcohol consumption and the development of other interventions in this regard. For example, including alcohol consumption in the Quality Outcomes Framework may lead to better recording of alcohol in the United Kingdom (as in the case of smoking ( 35 )) and ultimately the identifi cation of patients at high risk of liver disease and interventions to reduce future cirrhosis development.
We have determined that compensated patients of unspecifi ed etiology had an excess risk of non-liver-related neoplasm compared with the general population. Th ere are several possible reasons for this excess mortality. First, although we have shown that the excess is not due to diff erences in distributions of age, sex, and smoking status between people with cirrhosis and those without the disease, the excess non-liver neoplasm mortality between these two groups could be due to residual confounding. For example, social deprivation has recently been associated with cancer mortality ( 36 ). With respect to the association between the incidence of cirrhosis and socio-economic class, the current literature is limited, but if a positive relationship does exist then diff erences in deprivation between those with and without cirrhosis could explain some of the excess we report. Future research is required to investigate the eff ect of deprivation on excess mortality.
Second, as patients with cirrhosis of unspecifi ed etiology undergo several tests (similar to those used to detect cancer), these patients are consequently likely to have more incidental fi ndings, e.g., nonspecifi c and pancreatic cancer, compared with those without cirrhosis. Ascertainment bias, therefore, may explain why people with unspecifi ed cirrhosis are at a higher risk of dying from cancer compared with the general population.
Th ird, patients with cirrhosis are known to have comorbidities that may infl uence excess mortality ( 37 ) . However, statistically, we cannot adjust for particular comorbidities, as they are part of the fi nal common pathway to the specifi c causes of death. For example, myocardial infarction and congestive heart failure are comorbidities that are necessary for the outcome of circulatory death and, therefore, should not be treated as confounders in the context of our study.
It is biologically plausible that people with unspecifi ed cirrhosis may truly be of higher risk of non-liver neoplasm than those without the disease of similar age and sex. It has long been reported that cryptogenic cirrhosis (analogous to our unspecifi ed group) is associated with non-alcohol fatty liver disease ( 38 ) , which in turn is related to obesity, and there are several prospective epidemiological studies that have demonstrated a direct association between being overweight and risk of cancer ( 39, 40 ) . It has been estimated that ~20% of cancers are caused by excess weight ( 40 ) . Th erefore, the excess neoplastic death we fi nd in compensated unspecifi ed patients may be explained by a higher level of obesity present in those with unspecifi ed cirrhosis than those without the disease of similar age and sex. However, we cannot test for this inference statistically, as it may be misleading to adjust for patients' weight, as the timing of measurement may be infl uenced by disease stage. For example, patients are likely to have been fi rst weighted with cirrhosis at their presentation or decompensation and therefore could be overweight due to having ascites or those with cancer could lose weight dramatically due to cancer cachexia or the eff ects of chemotherapy.
CONCLUSION
In summary, our study has described the cause-specifi c mortality of a comprehensive and heterogeneous population of people with cirrhosis in England. Th e causes of excess death in people with liver cirrhosis vary by the underlying cause of liver disease and the stage of disease. Patients of alcoholic cirrhosis, chronic viral
